Survival in pulmonary hypertension in Spain: insights from the Spanish registry

A pulmonary hypertension (PH) registry (Spanish Registry of Pulmonary Arterial Hypertension) was undertaken to analyse prevalence, incidence and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Spain, and to assess the applicability of recent survival prediction equations. Voluntary reporting of previously diagnosed and incident PAH or CTEPH cases (July 2007–June 2008) was performed. Demographic, functional and haemodynamic variables were evaluated. 866 patients with PAH and 162 with CTEPH were included. PAH associated with toxic oil syndrome and pulmonary veno-occlusive disease were reported for the first time in a PAH registry. Estimated prevalences were as follows: PAH, 16 and CTEPH, 3.2 cases per million adult inhabitants (MAI). Estimated incidences were as follows: PAH, 3.7 and CTEPH, 0.9 cases per MAI per yr. 1-, 3- and 5-yr survival was 87%, 75% and 65%, respectively, with no differences between PAH and CTEPH. Male sex, right atrial pressure and cardiac index were independent predictors of death. Matching between observed survival and that predicted by different equations was closer when the characteristics of the cohorts were similar. Epidemiology and survival of PAH patients in the Spanish registry are similar to recent registries. Characteristics of the population from which survival prediction equations are derived influence their applicability to a different cohort. CTEPH is much less prevalent than PAH, although has a similar survival rate.

[1]  J. Barberà,et al.  Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry , 2011, Circulation.

[2]  J. Kline,et al.  Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association , 2011, Circulation.

[3]  W. Klepetko,et al.  Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. , 2011, The Journal of thoracic and cardiovascular surgery.

[4]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[5]  MarcHumbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010 .

[6]  S. Suissa,et al.  Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. , 2010, Circulation.

[7]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[8]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[9]  N. Lee,et al.  Diagnosis and assessment of pulmonary arterial hypertension , 2010 .

[10]  Sanjiv J. Shah,et al.  Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation , 2009, European Respiratory Journal.

[11]  G. Filippatos,et al.  Guidelines for the diagnosis and treatment of pulmonary hypertension , 2009 .

[12]  M. de Pauw,et al.  The Belgian Eisenmenger syndrome registry: Implications for treatment strategies? , 2009, Acta cardiologica.

[13]  C. Leroyer,et al.  Chronic thromboembolic pulmonary hypertension: a tribute to pulmonary endarterectomy , 2008, European Respiratory Journal.

[14]  M. Zwahlen,et al.  Epidemiology of pulmonary hypertension: new data from the Swiss registry. , 2008, Swiss medical weekly.

[15]  P. Corris,et al.  Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[16]  S. Rich,et al.  A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.

[17]  J. McMurray,et al.  An epidemiological study of pulmonary arterial hypertension , 2007, European Respiratory Journal.

[18]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[19]  T. Welte,et al.  Goal-oriented treatment and combination therapy for pulmonary arterial hypertension , 2005, European Respiratory Journal.

[20]  Gérald Simonneau,et al.  Chronic thromboembolic pulmonary hypertension , 2004, European Respiratory Journal.

[21]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[22]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[23]  J. Levy,et al.  HIV (Human Immunodeficiency Virus) , 2002 .

[24]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[25]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[26]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[27]  C. Kittle,et al.  Pulmonary venoocclusive disease. , 1976, The Annals of thoracic surgery.